Stockscreener 앱 받기
23.06
6.60%
-1.63
전일 마감가:
$24.69
열려 있는:
$24.86
하루 거래량:
1.55M
Relative Volume:
0.83
시가총액:
$2.39B
수익:
$71.78M
순이익/손실:
$-295.28M
주가수익비율:
-7.2982
EPS:
-3.1597
순현금흐름:
$-271.85M
1주 성능:
-3.80%
1개월 성능:
+50.72%
6개월 성능:
+19.48%
1년 성능:
+82.00%
1일 변동 폭
$22.33
$24.86
1주일 범위
$22.33
$24.95
52주 변동 폭
$8.195
$24.95
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
23.06 | 2.39B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
NRIX Maintained by HC Wainwright & Co. -- Price Target Raised to $34 - GuruFocus
Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside - TradingView
NRIX Maintained by Truist Securities -- Price Target Raised to $34.00 - GuruFocus
RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33 - Moomoo
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $28 to $40 - Moomoo
Nurix stock price target raised to $34 by H.C. Wainwright By Investing.com - Investing.com India
Mizuho raises Nurix stock price target to $34 on Roche deal By Investing.com - Investing.com South Africa
Nurix stock price target raised to $34 by H.C. Wainwright - Investing.com UK
Baird reiterates Nurix stock Outperform rating at $33 target By Investing.com - Investing.com India
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside - TradingView
Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX) - Sahm
Nurix Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
NRIX Maintained by Stifel -- Price Target Raised to $40 - GuruFocus
NRIX Maintained by RBC Capital -- Price Target Raised to $33 - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.6% After Earnings Miss - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $40.00 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada - MarketBeat
NRIX Reiterates by BTIG -- Price Target Maintained at $32 - GuruFocus
BTIG Research Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
RBC Capital Raises Nurix Therapeutics Price Target to $33 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Nurix Therapeutics Reports Q2 Loss, Revenue Falls Short Of Expectations - Bitcoin World
Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates - FXStreet
NRIX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Q2 2026 Earnings: Financial Results, Risk Factors, and Forward-Looking Statements Overview - Minichart
Nurix Therapeutics, Inc. Files Form 8-K Announcing July 2026 Press Release and Nasdaq Listing Details - Minichart
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Nurix (NRIX) Reports Q2 Revenue Miss, Highlights Roche Collabora - GuruFocus
Is Nurix Therapeutics Inc (NRIX) Facing Valuation Concerns After - GuruFocus
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Globe and Mail
Enterprise value to EBIT forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics Expects to Receive $700 M Upfront Payment From Roche in 3Q - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results - MarketBeat
Nurix Therapeutics (NASDAQ: NRIX) widens loss but secures $700M Roche bexobrutideg collaboration - Stock Titan
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche - TradingView
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighWhat's Next? - MarketBeat
Nurix Therapeutics stock hits 52-week high at $24.93 By Investing.com - Investing.com South Africa
Nurix Therapeutics stock hits 52-week high at $24.93 - Investing.com
Precision Trading with Nurix Therapeutics Inc. (NRIX) Risk Zones - Stock Traders Daily
Price to sales forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics earnings loom: Roche deal impact in focus By Investing.com - Investing.com South Africa
Nurix Therapeutics earnings loom: Roche deal impact in focus - Investing.com
Nurix stock up 29% in a month: Here's what you should know - MSN
Nurix Therapeutics patents new SMARCA2-targeting PROTACs - BioWorld News
NRIX Q2'26 Earnings: EPS estimate is (0.72) USD - TradingView
Nurix Therapeutics outlines its pipeline strategy - Ad-hoc-news.de
Roche collaborates with Nurix Therapeutics to develop BTK degrader bexobrutideg for cancer and immune diseases - Select Science
Price to earnings forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
누릭스 테라퓨틱스 주식 (NRIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Jul 02 '26 |
Sale |
23.56 |
11,008 |
259,366 |
13,579 |
2.64%
자본화:
|
볼륨(24시간):